Aldeyra Therapeutics (ALDX) Stock Price, Quote, News & History | Benzinga

SPY768.72+0.29%QQQ718.31−0.01%BTC/USD82,454.46+0.75%DIA523.62+0.91%GLD377.86−0.48%TLT80.04+0.73%

Aldeyra Therapeutics Inc (ALDX) Stock Price, Quote, News & History

ALDXNASDAQ

Trade with Public

Trade with Public

$0.6651

N/A

Last update: Oct 20, 9:28 AM

$0.6651

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$0.65

Close

-

Volume / Avg.

1.32M / 1.17M

Day Range

$0.65 - $0.74

52 Wk Range

0.65 - 5.93

Market Cap

$40.12M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

5.94%

Days to Cover

3.02

Recent Aldeyra Therapeutics Inc News

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.

Vandana Singh

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.

Vandana Singh

Oil Prices Spike To $98, Stocks Dip After Israeli Attack On Iran's Gas Facilities

U.S. stocks fell ahead of the Fed decision after February PPI topped forecasts, while Brent crude surged above $108.

Piero Cingari

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.

Avi Kapoor

FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%

Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Get the full regulatory update here.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-22.02M

Investing Cash Flow (TTM)

40.98M

Financing Cash Flow (TTM)

-15.11M

Free Cash Flow (TTM)

-22.04M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

3.85M

Analyst Trends and Forecast

1

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$4.82M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.06

Earnings Yield % (TTM)

-57.13%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.63

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$15.30M

Total Cash

$45.09M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$15.30M

Repayment of Debt (TTM)

-$15.30M